Oestrogen-containing menopausal hormone therapy (MHT) is the gold standard for the treatment of vasomotor symptoms of the menopause. Although one may have a favourite formulation of oestrogen or of oestrogen and progestogen, there are times when that formulation does not suit a particular woman. This may be either because of stage of menopause, or medical history, or co-morbidities, or side-effects, or simply patient preference. One size does not always fit all.
This presentation will present real-life case histories where a modification of MHT delivery, dose, or formulation was required, and will discuss the evidence base for efficacy and safety in each case.